Background An angiomyolipoma usually occurs in the kidneys and rarely in the liver. Hepatic epithelioid angiomyolipoma (HEAML), a rare variant of angiomyolipoma, possesses malignant potential and mimics the imaging features of hepatocellular carcinoma. Sonazoid (R) (perfluorobutane microbubbles), a new contrast agent that facilitates hepatic parenchyma-specific Kupffer phase imaging on contrast-enhanced ultrasonography (CEUS), is useful for the detection and characterization of focal liver lesions. Case presentation A 30-year-old man with HEAML underwent CEUS using Sonazoid (R), in which new concepts for ultrasonography-based differentiation between HEAML and hepatocellular carcinoma were applied. Conclusions This case report provides clinicians and radiologists with a reference for distinguishing HEAML from hepatocellular carcinoma based on CEUS using Sonazoid (R).
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Med Ultrasound, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Huang Zhe,Xin Jun-yi,Li Kai-yan.Ultrasound contrast agent Sonazoid for the diagnosis of hepatic epithelioid angiomyolipoma: a case report[J].BMC GASTROENTEROLOGY.2021,21(1):doi:10.1186/s12876-021-02064-1.
APA：
Huang, Zhe,Xin, Jun-yi&Li, Kai-yan.(2021).Ultrasound contrast agent Sonazoid for the diagnosis of hepatic epithelioid angiomyolipoma: a case report.BMC GASTROENTEROLOGY,21,(1)
MLA：
Huang, Zhe,et al."Ultrasound contrast agent Sonazoid for the diagnosis of hepatic epithelioid angiomyolipoma: a case report".BMC GASTROENTEROLOGY 21..1(2021)
